NR1H4 and metabolic dysfunction-associated steatohepatitis: Tropifexor, also known as LJN452, is a highly potent hammerhead-type FXR agonist that is currently under clinical trials for NASH and PBC patients (Kremoser, 2021; Sanyal et al., 2023; Tully et al., 2017).